[
  {
    "ts": null,
    "headline": "Pfizer's New Chief Scientific Officer Charts R&D Vision For High And Low-Risk Investments",
    "summary": "Goldman Sachs hosted a meeting with Pfizer Inc’s (NYSE:PFE) newly appointed Chief Scientific Officer Chris Boshoff (effective January 1, 2025). The analyst maintains the Buy rating with a price target of $33. When discussing core capabilities at Pfizer, the commentary highlighted a strategic shift toward prioritizing efforts. The focus will be on opportunities expected to deliver the highest economic returns while maintaining a balanced portfolio of high-risk and low-risk projects. With an annua",
    "url": "https://finnhub.io/api/news?id=e5abeec16bc466dea4a7ea5fc70fedebc1c9d464f7700e28da8325d2bc2c4408",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733251950,
      "headline": "Pfizer's New Chief Scientific Officer Charts R&D Vision For High And Low-Risk Investments",
      "id": 131766730,
      "image": "https://media.zenfs.com/en/Benzinga/f59047c99df5e02599c85b94ae03a99a",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Goldman Sachs hosted a meeting with Pfizer Inc’s (NYSE:PFE) newly appointed Chief Scientific Officer Chris Boshoff (effective January 1, 2025). The analyst maintains the Buy rating with a price target of $33. When discussing core capabilities at Pfizer, the commentary highlighted a strategic shift toward prioritizing efforts. The focus will be on opportunities expected to deliver the highest economic returns while maintaining a balanced portfolio of high-risk and low-risk projects. With an annua",
      "url": "https://finnhub.io/api/news?id=e5abeec16bc466dea4a7ea5fc70fedebc1c9d464f7700e28da8325d2bc2c4408"
    }
  },
  {
    "ts": null,
    "headline": "Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion",
    "summary": "NVS is all set to strengthen its neuroscience pipeline with the addition of PTCT's Huntington's disease drug.",
    "url": "https://finnhub.io/api/news?id=199b992818064c88646424fd66d408204d8565b1428277bde64afde4a28b658e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733251020,
      "headline": "Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion",
      "id": 131760711,
      "image": "https://media.zenfs.com/en/zacks.com/f166d65586ad9d3236a947b8d942f4c9",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NVS is all set to strengthen its neuroscience pipeline with the addition of PTCT's Huntington's disease drug.",
      "url": "https://finnhub.io/api/news?id=199b992818064c88646424fd66d408204d8565b1428277bde64afde4a28b658e"
    }
  },
  {
    "ts": null,
    "headline": "Agios Pharmaceuticals: A Long Overdue Follow Up",
    "summary": "Agios Pharmaceuticals has one product on the market, PYRUKYND, which has seen limited sales to date. Read more on how the product is being evaluated to treat much larger indications.",
    "url": "https://finnhub.io/api/news?id=55b36f9e90ade6874d79983ce295cf0f8e76e304fa585de10ee322d26484c2a1",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733246467,
      "headline": "Agios Pharmaceuticals: A Long Overdue Follow Up",
      "id": 131759042,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/155151969/image_155151969.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Agios Pharmaceuticals has one product on the market, PYRUKYND, which has seen limited sales to date. Read more on how the product is being evaluated to treat much larger indications.",
      "url": "https://finnhub.io/api/news?id=55b36f9e90ade6874d79983ce295cf0f8e76e304fa585de10ee322d26484c2a1"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. stock outperforms competitors despite losses on the day",
    "summary": "Pfizer Inc. stock outperforms competitors despite losses on the day",
    "url": "https://finnhub.io/api/news?id=8acf99c5fe1ad131cda19a8d95147f9d248945bd16b146ba7d6a042a88e7a72c",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733244000,
      "headline": "Pfizer Inc. stock outperforms competitors despite losses on the day",
      "id": 131777350,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Pfizer Inc. stock outperforms competitors despite losses on the day",
      "url": "https://finnhub.io/api/news?id=8acf99c5fe1ad131cda19a8d95147f9d248945bd16b146ba7d6a042a88e7a72c"
    }
  },
  {
    "ts": null,
    "headline": "PPBT Stock Surges 150% on Superior Efficacy of PDAC Combo Therapy",
    "summary": "Purple Biotech stock surges 150.4% on reporting superior efficacy data from the mid-stage study of its combo therapy on pancreatic cancer patients.",
    "url": "https://finnhub.io/api/news?id=563feba5ecd2d15a7a21b3a3530263cc163a1d2759dc2533c74339e21fc2d550",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733243220,
      "headline": "PPBT Stock Surges 150% on Superior Efficacy of PDAC Combo Therapy",
      "id": 131766732,
      "image": "https://media.zenfs.com/en/zacks.com/e797ee31d4bee954c41ecfac218dc795",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Purple Biotech stock surges 150.4% on reporting superior efficacy data from the mid-stage study of its combo therapy on pancreatic cancer patients.",
      "url": "https://finnhub.io/api/news?id=563feba5ecd2d15a7a21b3a3530263cc163a1d2759dc2533c74339e21fc2d550"
    }
  },
  {
    "ts": null,
    "headline": "NVCR Stock Up as TTFields Therapy Meets Pancreatic Cancer Study Goals",
    "summary": "Novocure stock soars 49% as the late-stage study of TTFields therapy for treating pancreatic adenocarcinoma meets the primary endpoint of overall survival.",
    "url": "https://finnhub.io/api/news?id=33d17dfded928f5dec0f9906823c4a89a6fc8b70a363c6acfb4f9ce689bfaf8b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733237760,
      "headline": "NVCR Stock Up as TTFields Therapy Meets Pancreatic Cancer Study Goals",
      "id": 131755517,
      "image": "https://media.zenfs.com/en/zacks.com/4658663242c3a61dee3fef55a1bf4887",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Novocure stock soars 49% as the late-stage study of TTFields therapy for treating pancreatic adenocarcinoma meets the primary endpoint of overall survival.",
      "url": "https://finnhub.io/api/news?id=33d17dfded928f5dec0f9906823c4a89a6fc8b70a363c6acfb4f9ce689bfaf8b"
    }
  }
]